NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
12.23
-0.58 (-4.53%)
At close: Nov 3, 2025, 4:00 PM EST
12.30
+0.07 (0.57%)
After-hours: Nov 3, 2025, 7:41 PM EST
NovoCure Stock Forecast
Stock Price Forecast
The 7 analysts that cover NovoCure stock have a consensus rating of "Buy" and an average price target of $28.64, which forecasts a 134.18% increase in the stock price over the next year. The lowest target is $14.5 and the highest is $42.
Price Target: $28.64 (+134.18%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NovoCure stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $38 → $42 | Strong Buy | Maintains | $38 → $42 | +243.42% | Oct 30, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $25 → $23 | Hold | Maintains | $25 → $23 | +88.06% | Oct 27, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $40 → $15 | Buy → Hold | Downgrades | $40 → $15 | +18.56% | Jul 25, 2025 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +145.30% | Jul 8, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $34 | Buy | Reiterates | $34 | +178.00% | Jun 27, 2025 |
Financial Forecast
Revenue This Year
662.93M
from 605.22M
Increased by 9.54%
Revenue Next Year
700.71M
from 662.93M
Increased by 5.70%
EPS This Year
-1.43
from -1.56
EPS Next Year
-1.52
from -1.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 696.2M | 775.9M | |||
| Avg | 662.9M | 700.7M | |||
| Low | 626.5M | 645.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.0% | 17.0% | |||
| Avg | 9.5% | 5.7% | |||
| Low | 3.5% | -2.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.38 | -1.25 | |||
| Avg | -1.43 | -1.52 | |||
| Low | -1.51 | -1.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.